Early trials of a vaccine that targets a specific gene found in tumors, known as KRAS, has proven to be effective in 84% of patients who had pancreatic or colorectal cancers recur after their initial treatment, according to researchers at Memorial Sloan Kettering Cancer Center in New York City who co-led the study.
